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Objective. To investigate the role of macrophage migration inhibitory factor (MIF) in the pathogenesis of ankylosing spondylitis (AS).
Methods. Patients who met the modified New York criteria for AS were recruited for the study. Healthy volunteers, rheumatoid arthritis patients, and osteoarthritis patients were included as controls. Based on the annual rate of increase in modified Stoke AS Spine Score (mSASSS), AS patients were classified as progressors or nonprogressors. MIF levels in serum and synovial fluid were quantitated by enzyme-linked immunosorbent assay. Predictors of AS progression were evaluated using logistic regression analysis. Immunohistochemical analysis of ileal tissue was performed to identify MIF-producing cells. Flow cytometry was used to identify MIF-producing subsets, expression patterns of the MIF receptor (CD74), and MIF-induced tumor necrosis factor (TNF) production in the peripheral blood. MIF-induced mineralization of osteoblast cells (SaOS-2) was analyzed by alizarin red S staining, and Western blotting was used to quantify active b-catenin levels.
Results. Baseline serum MIF levels were significantly elevated in AS patients compared to healthy controls and were found to independently predict AS progression. MIF levels were higher in the synovial fluid of AS patients, and MIF-producing macrophages and Paneth cells were enriched in their gut. MIF induced TNF production in monocytes, activated bcatenin in osteoblasts, and promoted the mineralization of osteoblasts.
Conclusion. Our findings indicate an unexplored pathogenic role of MIF in AS and a link between inflammation and new bone formation.
Ankylosing spondylitis (AS) is a chronic inflammatory form of arthritis that predominantly affects the axial joints and has a global prevalence of ;1% (1). Disease progression is marked by osteoproliferation and bone fusion in the axial joints, causing considerable loss of mobility (2) . Approximately 30-40% of patients experience rapid disease progression (3) . Delays in the diagnosis of AS and initiation of therapy may contribute to undeterred progression (4) . Despite the fact that 90% of AS patients are positive for the HLA-B27 gene, the pathogenesis of inflammation and spinal fusion is not well understood (5) . The co-occurrence of subclinical gut inflammation in ;50% of AS patients indicates that the gut/joint axis might be critical to establishment of the disease (6) .
Several studies have characterized the inflammatory immune cell subsets that are enriched in AS patients (7) (8) (9) . Systemic overexpression of interleukin-23 (IL-23) in mice was found to trigger a subset of CD31CD4-CD8-RORgt1 entheseal resident T cells that have the capacity to induce bone formation (10) . However, in human studies, such pathogenic cells that can induce both inflammation and bone formation have not been identified to date. Due to constraints in accessing spinal tissue, new bone formation has been difficult to study. Tumor necrosis factor inhibitors (TNFi) are used to treat symptomatic AS patients who do not respond to nonsteroidal antiinflammatory drugs (NSAIDs) (11) . Initial observational studies failed to show any disease-modifying potential of TNFi in AS in the first 2 years of follow-up (12) (13) (14) . However, recent studies have shown that early and sustained treatment with TNFi may help slow spinal fusion (15) .
Autoantibodies have previously been reported in AS (16) (17) (18) . High titers of autoantibodies to the invariant chain (CD74) of major histocompatibility complex (MHC) class II are seen in spondyloarthritis (19, 20) . CD74, expressed on the surface of antigen-presenting cells, is a high-affinity receptor for macrophage migration inhibitory factor (MIF) (21) . MIF is a potent proinflammatory cytokine implicated in several diseases (22) . It plays a key role in the development of chronic colitis in mouse models (23) . Elevated serum MIF levels have been reported in AS (24) . Although the role of MIF in bone formation has been a subject of controversy (25, 26) , high levels of MIF transcripts have been found in murine neonatal calvaria (27) , and CD74-knockout mice show enhanced osteoclastogenesis (28) . Binding of MIF to CD74 initiates a downstream signaling pathway through ERK-1/2 leading to cell proliferation (21) . CD74 has also been reported to undergo regulated intramembrane proteolysis involving a series of proteolytic cleavages in endocytic vesicles that release its cytosolic N-terminal fragment, which localizes into the nucleus and activates NF-kB (29) .
We hypothesized that perturbations in the MIF-CD74 axis could be the missing link between inflammation and new bone formation seen in AS. To test this hypothesis, we quantified MIF levels in the sera and tissues of AS patients and tested whether higher baseline serum MIF levels predict radiographic progression. We characterized CD74 expression in immune subsets and studied the effect of MIF signaling in peripheral blood mononuclear cells (PBMCs). We tested whether baseline serum MIF levels could predict AS progression. Last, we explored the effect of MIF on mineralization and b-catenin stabilization in SaOS-2 cells, a model cell line for mature human osteoblasts.
PATIENTS AND METHODS
Patients and samples. AS patients satisfying the modified New York criteria (30) were recruited from the Toronto Western Hospital spondyloarthritis clinic. Healthy volunteers were recruited as controls. Permission for the study was obtained from the institutional research ethics board, and informed consent was obtained from all subjects. Baseline serum samples were obtained from patients and controls at the first visit and cryopreserved at 2808C. Baseline clinical features of the AS patients are shown in Table 1 . All patients were followed up systematically, clinical variables were recorded annually, and radiographs were obtained every 2 years. Since this was a study of progression, AS patients had to have at least 2 sets of radiographs available to be included in the study. Patients receiving NSAIDs and those receiving TNFi received regular daily doses during the follow-up period. Progressors were defined as those who had an increase in the modified Stoke AS Spine Score (mSASSS) (31) of $1 unit/ year. We planned a sensitivity analysis using an alternate definition of progression: development of at least 1 new syndesmophyte during follow-up. Synovial fluid samples collected from the inflamed peripheral joints of AS patients and disease controls (rheumatoid arthritis [RA] Cell isolation and culture. PBMCs from AS patients and healthy controls were isolated by density-gradient centrifugation after layering blood on Ficoll-Paque (GE Healthcare) and cultured in complete RPMI medium (10% fetal bovine serum [FBS], 2 mM L-glutamine, and 50 mM b-mercaptoethanol) at 378C. The human osteosarcoma cell line SaOS-2 (Sigma-Aldrich) was cultured using complete McCoy's 5A medium (10% FBS and 2 mM L-glutamine) at 378C. Primary human osteoblasts (a kind gift from Professor Johanne Martel-Pelletier, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada) were isolated as previously described (32) . Osteogenic medium was prepared by supplementing complete McCoy's 5A medium with 50 mg/ml ascorbic acid 2-phosphate, 10 mM b-glycerophosphate, and 10 nM dexamethasone (all from Sigma-Aldrich). All cultures were supplemented with antibiotic/ antimycotic solution (Gibco) at concentrations recommended by the manufacturer.
Ex vivo assays. For estimating MIF-induced TNF production, PBMCs from healthy controls were treated with or without 50 ng/ml of recombinant human MIF (rhMIF; BioLegend) for 4 hours at 378C in the presence of brefeldin A (BioLegend). The cells were harvested, stained, and analyzed by flow cytometry. For inhibition experiments, the cells were pretreated for 1 hour with the signal peptide peptidase-like 2a (SPPL2a) inhibitor (Z-LL) 2 ketone (EMD Millipore) before addition of rhMIF.
Enzyme-linked immunosorbent assay (ELISA). MIF levels were quantitated in the synovial fluid and baseline serum samples using a Human MIF Quantikine ELISA Kit (R&D Systems) following the manufacturer's instructions.
Flow cytometry. Cells were stained for the surface and intracellular markers described above, acquired using a FACSCanto II system and FACSDiva software (Becton Dickinson). All analyses were performed using FlowJo version 10 (Tree Star).
Western blotting. SaOS-2 cells were treated with 0.25 mg/ml of recombinant human interferon-g (rhIFNg; BioLegend) for 72 hours to induce CD74, washed, and treated with different doses of rhMIF for 5 hours. Cells were lysed with a buffer containing 20 mM Tris HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P40 substitute, and protease inhibitor cocktail (Bioshop). For inhibition experiments, the cells were pretreated for 1 hour with the SPPL2a inhibitor (Z-LL) 2 ketone (EMD Millipore) or the ERK inhibitor FR180204 (R&D Systems) before addition of rhMIF. Proteins in the cell lysate were quantitated using a BCA Protein Assay kit (Pierce), and an equal amount of protein from each treatment group was electrophoresed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted using antibody against active nonphosphorylated b-catenin (the stable and functional form). GAPDH was used as the loading control.
Mineralization assays. SaOS-2 cells and primary human osteoblasts obtained from 3 surgical samples were seeded onto 96-well plates (2,500 cells/well) and incubated with 0.25 mg/ml of rhIFNg in complete McCoy's 5A medium for 72 hours. The cells were cultured in fresh osteogenic medium containing the indicated doses of rhMIF with the medium replaced every 3 days, whereas control cells were only cultured in osteogenic medium with vehicle control. At 2 weeks of MIF stimulation, the cells were washed, fixed, and stained with alizarin red S to visualize mineralization. Images of entire wells were captured using an EVOS FL Cell Imaging System (Life Technologies) and analyzed using Fiji software. The area of mineralization was quantified by converting the images to grayscale, and after adjusting the threshold to eliminate background noise, the total area was calculated in terms of pixel intensity. The threshold value was kept constant across images being compared. In addition, at 2 weeks of MIF stimulation (31.25 ng/ml), total RNA was extracted using an RNeasy Mini kit (Qiagen) and reverse transcribed using the First Strand Synthesis Kit (Qiagen). The complementary DNA samples were loaded onto a Human Osteogenesis RT 2 Profiler PCR Array according to the manufacturer's instructions (Qiagen). C t values were analyzed by the DC t method using Qiagen's online web analysis tool. The fold change from the control group was calculated as 2
. All data were normalized to HPRT1.
Immunohistochemistry and colocalization. Terminal ileal mucosa biopsy specimens were obtained from 11 AS patients (see Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40175/abstract, for clinical information) and 11 healthy controls who underwent colonoscopy. The AS patients included in the study had no clinical symptoms of bowel inflammation, and healthy controls had no symptoms of intestinal inflammation and were undergoing ileocolonoscopy for routine evaluation. Immunohistochemical analysis of ileal samples was performed as previously described (9) . Paraffinembedded sections (5 mm thick) were stained with hematoxylin and eosin for histologic evaluation of inflammation. Mouse monoclonal anti-human MIF was added at a dilution of 1:100 and incubated for 1 hour at room temperature. Isotype control antibody was used as a negative control. The number of MIF-positive cells was determined by counting the reactive cells from 3 randomly selected high-power microscopic fields (original magnification 3 250). To identify the cellular source of MIF, double staining for MIF and CD3 (T cells), CD19 (B cells), CD68 (macrophages), and a-defensin 5 (Paneth cells) was performed on paraffin-embedded sections, and the sections were treated with FITC or rhodamine red anti-mouse or anti-rabbit antibodies, plus RNasin (200 ng/ml) and counterstained using DAPI (Life Technologies). Confocal microscopy was used to examine fluorescence staining.
Statistical analysis. The Mann-Whitney test was used to calculate statistical significance of continuous variables in all analyses unless otherwise indicated (GraphPad Prism version 5). Logistic regression analysis (SPSS version 23) was conducted to identify independent baseline predictors of progression. Baseline values for age, disease duration, sex, HLA-B27 positivity, markers of inflammation (erythrocyte sedimentation rate and C-reactive protein), disease scores (mSASSS and Bath AS Disease Activity Index), serum MIF, smoking status (yes/no), NSAID use during follow-up (yes/no), and TNFi use during follow-up (yes/no) were used as covariates, and progression (yes/no) was the dependent variable. The final reduced model was created with variables that were significant in the full model.
RESULTS
Baseline serum MIF levels are elevated in AS patients and predict radiographic progression of disease. Serum MIF levels were quantitated and compared in 147 AS patients (113 men) and 61 healthy controls (27 men) at baseline. The mean 6 SD age of the AS patients (37.58 6 13.74 years) was not statistically different from that of the healthy controls (34.14 6 12.25 years). Baseline serum MIF levels were found to be significantly elevated in AS patients compared to healthy controls (mean 6 SEM 51.98 6 25.18 ng/ml versus 12.93 6 6.55 ng/ml; P , 0.001) ( Figure 1A ). Serum levels of MIF were not significantly altered in Figure 1 . Macrophage migration inhibitory factor (MIF) levels in the serum, synovial fluid, and ileum of patients with ankylosing spondylitis (AS), healthy controls (HC), and disease controls. A, Baseline serum levels of MIF, quantified by enzyme-linked immunosorbent assay, in healthy controls (n 5 61) compared to patients with AS (n 5 147), AS nonprogressors (n 5 92) compared to AS progressors (n 5 55), and AS patients receiving tumor necrosis factor inhibitors (TNFi; n 5 26) compared to AS patients not receiving TNFi (n 5 121). * 5 P , 0.05; *** 5 P , 0.001. NS 5 not significant. B, Levels of MIF in the synovial fluid of patients with AS (n 5 13), patients with rheumatoid arthritis (RA; n 5 8), and patients with osteoarthritis (OA; n 5 5). * 5 P 5 0.03 by Kruskal-Wallis test and Dunn's post hoc test. C, Quantification of MIFproducing cells in ileal sections from healthy controls (n 5 11) and AS patients (n 5 11) after immunohistochemical staining. *** 5 P , 0.0001. Symbols indicate individual subjects; horizontal lines and error bars show the mean 6 SEM.
patients who received treatment with TNFi compared to TNFi-naive patients ( Figure 1A) .
As described in Patients and Methods, AS patients who had an increase in the mSASSS of $1 unit/year were defined as progressors. Serum MIF levels were significantly higher in progressors than in nonprogressors (mean 6 SEM 58.32 6 26.18 versus 48.82 6 24.40; P 5 0.025) ( Figure 1A ). In multivariable logistic regression analysis, baseline MIF levels and the interaction of MIF levels and baseline mSASSS were independent predictors of AS progression ( Table 2 ). The use of TNFi was associated with ;90% decreased odds of progression (odds ratio [OR] 0.12, P 5 0.02). Men were more likely to experience progression (OR 6.57, P 5 0.015), while HLA-B27-positive individuals were less likely to experience progression (OR 0.178, P 5 0.004). Baseline mSASSS was significantly associated with progression (OR 1.588, P 5 0.001).
Due to the strong effect of baseline damage on progression, we assessed the interaction of MIF levels and baseline mSASSS. There was a strong interaction between mSASSS and MIF levels in the regression analysis (P 5 0.003) ( Table 2 ). There appears to be an effect of MIF levels on progression only in those with syndesmophytes at baseline (Supplementary Table 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40175/abstract). The highest probability of progression was seen in AS patients who had baseline syndesmophytes and high MIF levels, who were men (93% of those with baseline syndesmophytes and high MIF levels), or who were smokers (87% of those with baseline syndesmophytes and high MIF levels). In a sensitivity analysis, all patients who developed at least 1 new syndesmophyte had a rate of progression of $1 mSASSS unit/year. Therefore, using an alternate definition for progression did not reclassify any patient and thus did not change the results.
Elevated MIF expression in the inflamed peripheral joints and ileum of AS patients. Synovial fluid samples obtained from the large peripheral joints of AS patients were analyzed for MIF levels. Compared to OA patients, synovial fluid MIF levels were significantly higher in AS patients ( Figure 1B) . There was no significant difference in synovial fluid MIF levels between AS patients and RA patients.
Subclinical bowel inflammation is known to occur in ;50-60% of AS patients (6) . We obtained ileal tissue from 11 AS patients and 11 healthy controls and performed immunohistochemical analysis to reveal MIF-producing cells (Supplementary Figure 1A Figure 1E ) were predominantly associated with MIF production. PBMCs from AS patients and healthy controls were analyzed for intracellular MIF expression. MIF is a nonclassic cytokine and is not secreted via the Golgi network (33) . It was therefore not necessary to block protein transport to analyze intracellular MIF. MIF was detected by intracellular flow cytometric staining in major immune cell subsets ( Supplementary Figures 2A  and B) . However, the frequencies of MIF-producing cell subsets in peripheral blood were not statistically different between AS patients and healthy controls (Supplementary Figure 2C ). These findings indicate that MIFproducing macrophages and Paneth cells are specifically enriched in the ileum of AS patients.
Decreased levels of intracellular CD74 in monocytes from AS patients. In order to further dissect the role of MIF in AS, we characterized the expression of its high-affinity receptor, CD74, in PBMCs by flow cytometry. CD74 has been reported to belong to a class of surface receptors that get cleaved at the transmembrane domain to generate an intracellular fragment that can translocate to the nucleus and act as a transcription factor (29). We therefore used 2 different antibodies, clones 5-329 and PIN. Figure 3B) revealed that 90% were monocytes (CD141) and B cells (CD191). Less than 10% were T cells (CD31) or lineage negative cells (CD3-CD19-CD14-). CD74 was found to be expressed on almost all B cells and monocytes and was not restricted to any subset (Supplementary Figure 3C) . However, the intensity of CD74 expression on these cells was considerably variable. CD191 B cells expressed higher levels of CD74 than CD141 cells. We then compared CD74 expression levels in cellular subsets from AS patients and healthy controls. Although surface CD74 intensities were not altered in monocytes from AS patients (Figure 2A) , intracellular domain CD74 levels were significantly lower in AS patients than in healthy controls ( Figure 2B) . B cells, in contrast, did not exhibit differences in intensities of surface and intracellular CD74 between AS patients and healthy controls (Supplementary Figures 3D and E (Figures 2C and D) . TNF is a key inflammatory mediator and a therapeutic target in AS (11) . In order to confirm that the action of MIF was specific to monocytes, we analyzed TNF induction on live gated B cells (Supplementary Figure 3F) and T cells (Supplementary Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40175/abstract). This effect was not seen in other cell subsets (data not shown).
In addition, to assess whether regulated intramembrane proteolysis of CD74 plays any role in TNF production in monocytes, we inhibited SPPL2a, the enzyme known to cleave the transmembrane domain of CD74, an important step preceding generation of the CD74 N-terminal fragment by regulated intramembrane proteolysis. Treatment with the inhibitor ([Z-LL] 2 ketone) reduced MIF induction of monocyte intracellular TNF (Figures 2C and D) . Thus, by inducing monocyte-specific TNF production, the MIF-CD74 axis possibly plays an upstream proinflammatory role in AS.
MIF induces mineralization of SaOS-2 cells and primary osteoblasts in a dose-dependent manner. Our data indicated that MIF was an independent predictor of spinal progression in AS. We therefore investigated whether MIF directly activates osteoblasts. To test this, we studied the effect of rhMIF on SaOS-2 cells under osteogenic conditions. SaOS-2 is a human osteosarcoma cell line and does not express CD74 under physiologic conditions. It has been reported that levels of proinflammatory cytokines such as IFNg and TNF are higher in AS sera (34) and can induce MHC class II (35) . Therefore, to mimic an inflammatory milieu and induce the expression of MHC class II, we treated the SaOS-2 cells and primary osteoblasts with rhIFNg for 72 hours. The dose of rhIFNg was titrated for optimal induction of CD74 (data not shown). An increase in surface expression of CD74 was observed with IFNg treatment (Supplementary Figure 4B) . All experiments were replicated with primary human osteoblasts. SaOS-2 cells and primary osteoblasts were cultured under osteogenic conditions in the continuous presence of rhMIF for 2 weeks. MIF induced significantly higher levels of mineralization and calcium deposition by the cells in a dosedependent manner, as detected by alizarin red S staining ( Figures 3A and B and Supplementary Figures 4C  and D) . Prolonged culture of SaOS-2 cells and primary osteoblasts at high concentrations of MIF was found to reduce viability, leading to poor mineralizing activity.
To further investigate the mechanisms involved in MIF-induced mineralization, the gene expression profile in SaOS-2 cells and primary osteoblasts was analyzed using a polymerase chain reaction array. We found that of the 84 genes involved in osteogenesis that were tested, 19 were up-regulated (.1.5 fold change, P , 0.05) in SaOS-2 cells and 16 were up-regulated in primary osteoblasts ( Figure 3C , Supplementary Figure  4E , and Supplementary Tables 4 and 5). These results suggest that MIF plays a direct role in enhancing mineralization by osteoblasts and could potentially stimulate pathologic bone growth in AS.
Activation of b-catenin by MIF signaling. We wanted to determine whether MIF-induced mineralization of SaOS-2 cells was mediated through activation of the canonical Wnt/b-catenin pathway. In order to understand the mechanistic basis of MIF-induced mineralization, we cultured SaOS-2 cells under inflammatory conditions, treated them with rhMIF for 5 hours, and determined if b-catenin was activated. A dosedependent induction of an active, nonphosphorylated form of b-catenin was seen ( Figures 3D and E) . Thus, we found that MIF triggers stabilization of b-catenin, a known mediator of osteoblastic activity. MIF signaling via CD74 is mediated by the ERK pathway. Blocking ERK phosphorylation with the ERK-1/2-specific inhibitor FR180204 decreased active b-catenin induction by MIF in a dose-dependent manner ( Figure 3F ). We inhibited regulated intramembrane proteolysis and generation of the CD74 N-terminal fragment by inhibiting SPPL2a. Treatment with the SPPL2a inhibitor (Z-LL) 2 ketone stabilized CD74 and increased its intracellular availability in SaOS-2 cells (Supplementary Figure 4F) . However, induction of active b-catenin by MIF was not diminished following inhibition of SPPL2a, and in fact was slightly higher (Supplementary Figure 4G) . These findings indicate that MIF signaling through full-length CD74 via the ERK pathway, and not generation of the CD74 N-terminal fragment, is critical for activating bcatenin.
DISCUSSION
We propose that the innate immune cytokine MIF plays a pathogenic role in AS by acting as a mediator of both inflammation and bone formation, two cardinal features of AS (36) . We found that AS patients had significantly elevated serum and synovial fluid MIF levels, and MIF-producing cells were enriched in the gut of AS patients. Elevated tissue levels of MIF have previously been reported in psoriasis (37) , uveitis (38) , and inflammatory bowel disease (23) , all of which are extraarticular manifestations seen in AS patients (39) . We found that baseline serum MIF levels predict radiographic progression in AS patients as well as trigger osteoblastic activity in vitro. These data indicate that MIF should be further explored as a prognostic biomarker of disease progression and a therapeutic target for early intervention in AS.
CD74 is known to be the high-affinity receptor for MIF. Co-receptors such as CXCR2, CXCR4, and CD44 (40) have been reported to be involved in transducing MIF signals along with CD74. Regulated intramembrane proteolysis is considered to be an important mechanism for mobilizing dormant transcription factors (41) . We showed that monocytes from AS patients have lower levels of intracellular domain CD74, and this could be indicative of active regulated intramembrane proteolysis. Surface CD74 has an extremely short half-life and is rapidly replenished after internalization (42) . Inhibition of the intramembrane protease SPPL2a blocks regulated intramembrane proteolysis and increases intracellular CD74 availability while total CD74 protein levels are unaffected (43) . Persistent signaling by circulating MIF in AS patients might be responsible for cleavage and loss of intracellular domain CD74. It is not clear why this effect is specific to monocytes, but it could be associated with co-receptor availability. We found that MIF activates CD141 monocytes to produce TNF, an important proinflammatory cytokine in AS (44) . MIF has previously been shown to be important for priming IL-17 responses in vivo (45) and could therefore act as a key mediator of inflammation in AS. Although the pathogenic significance is not clear, the presence of autoantibodies to CD74 in early spondyloarthritis (19,20) raises interesting possibilities, including possible MIF-like stimulatory effects through crosslinking of the receptor.
The Wnt, bone morphogenetic protein, and Notch signaling pathways can independently mediate osteoblast differentiation (46) . Our results indicate that MIF can directly mediate mineralization by osteoblasts in vitro, corroborating our finding that baseline MIF predicts radiographic progression. MIF was elevated in the synovial fluid of RA patients as well. It remains a mystery how several mediators that are elevated in both RA and AS can lead to the disparate outcomes of erosive disease and new bone formation, respectively. The paradoxical role of MIF in bone homeostasis indicates that additional factors govern the effect of MIF in inflammatory joint diseases.
MIF may play a physiologic role in osteoblast maturation since it is found to be expressed in murine neonatal calvaria (27) . MIF signaling through the MAP kinase pathway induces the production of prostaglandin E 2 (47) , an important molecule with bone anabolic properties (48) . We demonstrated that MIF stabilizes the active, nonphosphorylated form of b-catenin, a key mediator of the canonical Wnt pathway for osteoblast differentiation (49) . Specific inhibition of the ERK pathway significantly decreased the stabilization of bcatenin, providing mechanistic evidence of MIF action on osteoblasts.
Our data show that intracellular stores of MIF in major immune subsets in AS were not significantly altered from those in healthy controls. This indicates that either the secretion of MIF is differentially regulated in AS patients or the main source of pathologically high levels of MIF in AS could be nonimmune cells and/ or tissue-resident immune cells. Interestingly, nonimmune tissues known to produce MIF, such as the intestine, skin, and lungs, are the ones that maintain close contact with environmental antigens (22) . In this study, we characterized the MIF-producing cells in the ileum. To our knowledge, this is the first study showing colocalization of MIF with CD681 macrophages and Paneth cells, a subset of intestinal epithelial cells with antimicrobial functions. Certain intestinal pathogens such as Helicobacter pylori have been shown to trigger the release of MIF (50) . Since 50-60% of AS patients have subclinical gut inflammation (6) and our data showed enrichment of MIF-producing cells in the gut, we hypothesize that the gut could be the major site of initial MIF production.
AS progressors were more likely to be smokers, but smoking did not stand out in multivariable regression analysis. Smokers tended to have higher baseline mSASSS scores (data not shown). We did not analyze pack-years of smoking per person in this study, and this might have decreased our ability to show the true effect on spinal fusion. NSAID use did not affect progression, and this finding corroborated a recent randomized control trial of diclofenac use in AS patients (Effects of NSAIDs on Radiographic Damage in Ankylosing Spondylitis [ENRADAS]) (51).
In conclusion, MIF appears to have the unique ability to drive both inflammation and new bone formation and could play an important role in the pathogenesis of AS. Serum MIF levels were predictive of progressive spinal damage in AS patients. Further studies using animal models are warranted to understand the nature of MIF-producing subsets that localize to inflammatory tissues such as the skin, eye, and joints.
